Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
Vidya H Veldore,1,* Anuradha Choughule,2,* Tejaswi Routhu,1 Nitin Mandloi,1 Vanita Noronha,2 Amit Joshi,2 Amit Dutt,3 Ravi Gupta,1 Ramprasad Vedam,1 Kumar Prabhash2 1MedGenome Labs Private Ltd,, Bangalore, India; 2Tata Memorial Centre, Parel, Mumbai, India; 3The Advanced Centre for Treatment, Resear...
Enregistré dans:
Auteurs principaux: | Veldore VH, Choughule A, Routhu T, Mandloi N, Noronha V, Joshi A, Dutt A, Gupta R, Vedam R, Prabhash K |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/75a83c5f0528444c8a9f3e281fae022b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma
par: Kate I. Glennon, et autres
Publié: (2021) -
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
par: Natasha Honoré, et autres
Publié: (2021) -
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
par: Maha Elazezy, et autres
Publié: (2021) -
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
par: Lionel Larribère, et autres
Publié: (2021) -
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
par: Kate S, et autres
Publié: (2019)